In Gurugram, at Fortis Memorial Research Institute (FMRI), has accomplished an important turning point in the treatment of Sickle Cell Disease (SCD) through bone marrow (stem cell) transplantation surgery. Amid 2015 to 2024, the pediatrics haematology team treated 100 children, which record a complete persistence rate of approximately 87%. In cases with a fully matched sibling donor, the success rate reached an impressive 96%.
Why This Matters
Sickle Cell Disease is a genetic blood condition in which red blood cells convert into sickle-shaped, leading to long-lasting, enduring pain, persistent infections, organ injury, and reduced life expectation. Until now, treatment largely focused on managing symptoms, with few curative options available.
FMRI’s team has proven that stem cell transplantation can completely cure the disease, especially when conducted early—before severe complications set in. The doctors also achieved successful transplants using semi-matched family donors (haplo-identical transplants) and achieved a ~78% success percentage, suggestively increasing donor potentials for families.
Key Outcomes
- 100 paediatric SCD patients treated over 10 years
- ~87% total survival rate
- 96% success rate with matched sibling donors
- ~78% success rate with half-matched donor transplants
- Use of reduced-toxicity transplant techniques to enhance safety and recovery
Influence for Families
This discovery proves that Sickle Cell Disease can be cured—not just accomplished throughout life. Early detection, on-time recommendation to a transplant centre, and donor estimation dramatically improve the chances of success.
Conclusion
FMRI’s bone marrow transplant program has redefined sickle cell treatment in India. With constantly high success rates, improved safety protocols, and wider donor options, Fortis offers new hope to children and families while setting new values and morals in advanced haaematology care.